Table 3 The number of patients with responders or non-responders corresponding to cutoff values of eight serum inflammation indexes, and clinical features
Response (n) | No response (n) | |
|---|---|---|
NLR at baseline | ||
≤ 1.622 | 7 | 1 |
> 1.622 | 44 | 11 |
LMR at baseline | ||
≤ 3.173 | 19 | 0 |
> 3.173 | 32 | 12 |
PLR at baseline | ||
≤ 71.108 | 3 | 0 |
> 71.108 | 48 | 12 |
S II at baseline | ||
≤ 559.266 | 32 | 12 |
> 559.266 | 19 | 0 |
LMR at post treatment of second period | ||
≤ 5.987 | 46 | 11 |
> 5.987 | 6 | 1 |
LMR at post treatment of third period | ||
≤ 3.040 | 28 | 2 |
> 3.040 | 18 | 8 |
PLR at post treatment of third period | ||
≤ 151.516 | 22 | 10 |
> 151.516 | 24 | 1 |
S II at post treatment of second period | ||
≤ 174.574 | 9 | 1 |
> 174.574 | 43 | 11 |
BMI | ||
Underweight, | 8 | 1 |
Normal weight | 36 | 8 |
Overweight | 8 | 3 |
ECOG-PS | ||
0 | 14 | 5 |
1 | 38 | 7 |
Clinical stage | ||
II | 15 | 4 |
III | 26 | 7 |
IV | 11 | 1 |
Tumor site | ||
Upper | 3 | 0 |
Middle | 22 | 8 |
Lower | 27 | 4 |